

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Galileo - Biotech Innovation Fund S USD (Currency: USD)

ISIN: LU2226245095

a share class of Galileo - Biotech Innovation Fund which is a sub-fund of Galileo.

Management Company: IPConcept (Luxembourg) S.A., société anonyme

Website: www.ipconcept.com

Call +352 2602481 for more information.

The Commission de Surveillance du Secteur Financier is responsible for the supervision of IPConcept (Luxembourg) S.A., société anonyme in relation to this Key Information Document. This PRIIP is authorised in Luxembourg.

IPConcept (Luxembourg) S.A., société anonyme is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier.

Date of production of the Key Information Document: 19/02/2024

What is this product?

Type

The product is a share class of the sub-fund Galileo - Biotech Innovation Fund, which is part of Galileo (the "umbrella fund"), a Luxembourg investment fund (fonds commun de placement - FCP) of the umbrella type governed by Part I of the Luxembourg Law of 17 December 2010, as amended (2010 Law), and thus qualifies as a UCITS. The assets and liabilities of all sub-funds are segregated by law.

Term

The sub-fund has no maturity date. Notwithstanding this provision, the sub-fund may be dissolved at any time by the management company.

Objectives

Investment objective

The objective of the investment policy for the Galileo - Biotech Innovation Fund (the "sub-fund") is to achieve sufficient growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is established, regularly reviewed and adjusted where appropriate by the fund manager exclusively in accordance with the criteria that are defined in the investment objectives / investment policy. The sub-fund is not managed using an index as a benchmark.

Investment policy

The sub-fund is an equity fund. The sub-fund invests at least 51% of its net assets in biotech companies. A maximum of 49% of the net sub-fund assets may be invested in liquid assets. In principle, the sub-fund may invest in equities, bonds, money market instruments, certificates, other structured products (e.g. reverse convertible bonds, warrant-linked bonds, convertible bonds), target funds and fixed-term deposits, depending on the

market situation and the assessment of the fund management. Such certificates may be based on legally permissible underlying assets such as, e.g., equities, bonds, shares in investment funds, financial indices and foreign exchange. For hedging purposes or to increase the assets, the sub-fund may also use financial instruments whose value depends on the future prices of other assets ("derivatives"). Detailed information regarding the aforementioned and, if applicable, other investment opportunities for the fund can be found in the current sales prospectus.

Dividend policy

The income remains in the fund.

Subscription and redemption

Investors may, in principle, redeem their shares on any banking day in Luxembourg with the exception of 24 and 31 December. The redemption of shares may, in due consideration of investors' interests, be suspended if this proves necessary in exceptional circumstances.

Intended retail investor

The fund is aimed at all types of investors who pursue the goal of asset accumulation or asset optimisation and wish to invest in the long term. They should be able to bear losses up to the amount of the capital invested.

Depository


The depository of the fund is DZ PRIVATBANK S.A., société anonyme, with its registered office at L-1445 Strassen, Luxembourg, 4, rue Thomas Edison.

Further information

For the full criteria, please refer to the sales prospectus.

What are the risks and what could I get in return?

Risk indicator



The risk indicator is based on the assumption that you will hold the product for 5 years.

If you cash in the investment early, the actual risk may differ significantly and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will

lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 6 out of 7, which is the second-highest risk class. This rates the potential losses from future performance at a high level, and poor market conditions are very likely to impact our capacity to pay you.

Please be aware of currency risk if your reference currency differs from the currency of the product. You may receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

Other risks not included in the risk indicator may be materially relevant:

- Liquidity risk
- Operational risk.

Please see the prospectus for further information.

This product does not include protection against future market developments, so you could lose all or part of the capital invested.

Performance Scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate and favourable scenarios shown illustrate the worst, average and best performance of the product and an appropriate benchmark over the last ten years. The markets could develop in an entirely different way in the future.

Recommended holding period:		5 years	
Example Investment:		10,000 USD	
		If you exit after 1 year	If you exit after 5 years
Scenarios			
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress	What you might get back after costs	1,630 USD	760 USD
	Average return each year	-83.70%	-40.27%
Unfavourable	What you might get back after costs	4,390 USD	3,770 USD
	Average return each year	-56.10%	-17.72%
Moderate	What you might get back after costs	10,140 USD	11,580 USD
	Average return each year	1.40%	2.98%
Favourable	What you might get back after costs	15,010 USD	16,620 USD
	Average return each year	50.10%	10.69%

The stress scenario shows what you might get back in extreme market circumstances.

Unfavourable scenario: this scenario occurs in the case of an investment between July 2021 and December 2023 with an appropriate benchmark being used for the calculation, since fund data does not exist for the entire history.

Moderate scenario: this scenario occurs in the case of an investment between August 2014 and August 2019 with an appropriate benchmark being used for the calculation, since fund data does not exist for the entire history.

Favourable scenario: this scenario occurs in the case of an investment between February 2016 and February 2021 with an appropriate benchmark being used for the calculation, since fund data does not exist for the entire history.

What happens if IPConcept (Luxemburg) S.A., société anonyme is unable to pay out?

The default of IPConcept (Luxemburg) S.A., société anonyme has no direct impact on your payout, as the statutory regulation provides that in the event of the insolvency of IPConcept (Luxemburg) S.A., société anonyme, the special assets do not become part of the insolvency estate, but are maintained independently.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product performs, if applicable. The amounts shown here are illustrations based on an investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- 10,000 USD will be invested.

	If you exit after 1 year	If you exit after 5 years
Total costs	125 USD	719 USD
Annual cost impact (*)	1.3%	1.2% each year

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 4.2 % before costs and 3.0 % after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	We do not charge an entry fee.	0 USD
Exit costs	We do not charge an exit fee.	0 USD
Ongoing costs taken each year		
Management fees and other administrative or operating costs	1.04% of the value of your investment per year. This is an estimate based on actual costs over the last year.	104 USD
Transaction costs	0.21% of the value of your investment per year. This is an estimate of the costs incurred when we buy or sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	21 USD
Incidental costs taken under specific conditions		
Performance fees (and carried interest)	There is no performance fee for this product	0 USD

How long should I hold it and can I take money out early?

Due to the risk and return profile, we recommend a holding period of at least 5 years for this product.

You can, however, return the product in compliance with the return modalities stated in the sales prospectus. Early redemption can have a significant impact on the risk and return profile. The redemption may be temporarily suspended if there are circumstances which require a suspension and this is justified taking into account the interests of the investors.

How can I complain?

In case of complaints, you can write to IPConcept (Luxemburg) S.A., société anonyme at the address 4, rue Thomas Edison, L - 1445 Strassen, Luxembourg or send an email to info.lu@ipconcept.com. You can also find more information on the following website: www.ipconcept.com. Complaints about the person advising on or selling the product can be made directly to that person.

Other relevant information

Further information on the fund, the currently valid sales prospectus together with the appendix and the management regulations as well as the latest annual and semi-annual reports, each in German, can be obtained free of charge during normal business hours from the management company, the depositary as well as the distributor(s) and the paying agent(s).

Further practical information as well as the current unit prices can be obtained at any time from the homepage of the management company and free of charge from the above-mentioned offices. In addition, details of the current remuneration policy, including a description of how remuneration and other benefits are calculated and the identity of the persons responsible for allocating remuneration and other benefits, including the composition of the remuneration committee, if any, are available on the management company's website and may be obtained free of charge in hard copy from the above offices.

Tax regulations in the fund's home member state may affect your personal tax position. Please consult your tax advisor regarding the tax implications of investing in the fund.

This material information describes one share class of the fund. The prospectus and reports may contain information about all share classes of the fund. It is generally possible to exchange the shares of the share class for those of another share class. Details of any exchange possibilities and the associated costs can be found in the sales prospectus.

The management company can only be held liable on the basis of a statement contained in this document that is misleading, incorrect or inconsistent with the relevant parts of the sales prospectus.

Information on the past performance of the product for the last 10 years including the past performance scenario calculations can be found free of charge at: https://www.ipconcept.com/ipc/en/funds_overview.html.

Further documents can also be found free of charge on the management company's website at <https://www.ipconcept.com>.

Swiss investors can obtain copies of the prospectus (incl. management regulations or articles of association), the Key Information Document as well as the annual and semi-annual reports free of charge from the representative in Switzerland, IPConcept (Schweiz) AG, Münsterhof 12, CH-8022 Zurich. The paying agent in Switzerland is DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, CH-8022 Zurich.